Icos Pafase for sepsis discontinued
Executive Summary
Icos discontinues severe sepsis agent Pafase after Phase III study failed to meet primary efficacy endpoint of 28-day all-cause mortality. Icos commenced COMPASS trial in April 2001; the study had enrolled 1,250 patients of 2,500 planned. Icos hoped to gain approval for Pafase (recombinant human platelet-activating factor acetylhydrolase) based on the single study (1"The Pink Sheet" Aug. 27, 2001, p. 25). Icos has a second compound, IC14, in Phase II for community acquired pneumonia-related sepsis...
You may also be interested in...
Icos Pafase Phase III Sepsis Trial Will Collect Cost-Effectiveness Data
Icos will collect cost-effectiveness data in the Phase III trial for its sepsis treatment Pafase (recombinant platelet activating factor acetylhydrolase).
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.